Sage Therapeutics

372 articles about Sage Therapeutics

• 

  Pivotal Late-Stage Trial Shows Major Depressive Drug Significantly Reduces Symptoms

  6/15/2021

  The study drug is a once-daily, two-week therapy developed by Sage Therapeutics and Biogen for major depressive disorder (MDD) and postpartum depression (PPD).
• 

  Five VC Firms Repeatedly Flex Financial Muscles in Biopharma

  5/26/2021

  BioSpace looks at five of the top investor companies that support life sciences companies across the industry.

• Sage Therapeutics Joins MTV Entertainment Group and More Than 1,300 Leading Organizations to Participate in Inaugural Mental Health Action Day

  5/20/2021

  Creating a movement from the inside out – to break the stigma of mental health conditions and empower employees to be champions of brain health

• Sage Therapeutics to Host Sage Science Spotlight: SAGE-718 In Depth

  5/13/2021

  Debut webcast to provide deep dive on SAGE-718, the company’s lead neuropsychiatry product candidate being studied for cognitive disorders associated with NMDA receptor dysfunction, including Huntington’s, Parkinson’s, and Alzheimer’s diseases Webcast scheduled for 8:30 a.m. ET on Thursday, May 20

• Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

  5/4/2021

  Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the first quarter ended March 31, 2021.

• Sage Therapeutics to Present at Upcoming May Investor Conferences

  4/28/2021

  Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the following upcoming investor conferences in May: Bank of America Health Care Conference: fireside chat on Tuesday, May 11, 2021 at 10:15 am ET.

• Sage Therapeutics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021

  4/20/2021

  Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced it will host a live webcast on Tuesday, May 4, 2021 at 8:00 a.m. ET to announce first quarter 2021 financial results and discuss recent business updates.

• 

  Clinical Catch-Up: April 12-16

  4/19/2021

  It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look.

• Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint

  4/12/2021

  Statistically significant reduction in tremor score compared to placebo at Day 29 in adults with essential tremor SAGE-324 demonstrated a 36% reduction in upper limb tremor amplitude from baseline at Day 29 in the total studied population; in a more severe population (baseline TETRAS Upper Limb Item 4 & 12), SAGE-324 demonstrated a 41% reduction in upper limb tremor amplitude compared to baseline

• 

  Biogen and Sage’s Movement Disorder Therapy, SAGE-324 Reduces Tremor Score in Study

  4/12/2021

  Recently announced topline results from a Phase II study show SAGE-324, Sage Therapeutics’ investigational oral neuroactive steroid GABAA receptor positive allosteric modulator, significantly reduced tremor score in adult patients with essential tremor.

• Sage Therapeutics to Present at the Stifel 3rd Annual CNS Day

  3/24/2021

  Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced that the Company will participate in a fireside chat at the Stifel 3rd Annual CNS Day on Wednesday, March 31, 2021 at 8:00am ET.

• Sage Therapeutics Announces Continued Positive Zuranolone Data for Both 30 mg and 50 mg Doses in Open-Label SHORELINE Study in Patients with MDD

  3/17/2021

  Sage Therapeutics Announces Continued Positive Zuranolone Data for Both 30 mg and 50 mg Doses in Open-Label SHORELINE Study in Patients with MDD

• Sage Therapeutics Announces Departure of Chief Operating Officer

  3/16/2021

  Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today announced that Mike Cloonan, Sage’s Chief Operating Officer, is leaving the company effective May 3, 2021 to pursue other opportunities.

• Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress

  2/24/2021

  Reported positive interim data from Phase 3 open-label SHORELINE Study showing that more than 70% of patients successfully treated with zuranolone 30 mg needed two or fewer treatment courses over one year Progressed WATERFALL Study – now closed to enrollment – investigating zuranolone for as needed treatment of major depressive disorder with data anticipated in the first half of 2021

• Sage Therapeutics to Present at Upcoming Investor Conferences

  2/11/2021

  Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the following upcoming investor conferences:

• Sage Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021

  2/10/2021

  Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on Wednesday, February 24, 2021 at 8:00 a.m. ET to announce fourth quarter and full year 2020 financial results and discuss recent business updates.

• Sage Therapeutics Provides 2021 Corporate Strategy Update at J.P. Morgan Healthcare Conference

  1/7/2021

  Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that Chief Executive Officer, Barry Greene, will discuss the Company’s progress in becoming a leader in brain health in a corporate presentation at the 39th Annual J.P. Morgan Healthcare Conference.

• Sage Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021

  12/23/2020

  Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. ET.

• 

  A Bright Day for Two Companies as New CEOs Announced

  12/17/2020

  On Wednesday, Sage Therapeutics and Samsung Biologics announced that they had found just that in their new chief executive officers.

• Sage Therapeutics Announces the Appointment of Barry Greene as CEO

  12/16/2020

  Barry Greene, a world-class leader with global experience and a significant track record of success in R&D and commercialization, joins as part of plan to accelerate the Sage mission to deliver truly transformational medicines for people with brain health disorders Jeff Jonas to assume new role of Chief Innovation Officer, Chair of the Science and Technology Forum